IL20 and breast carcinoma: Because Ell3 is an additional factor to the triple complex of ER(α), GATA3 and FOXA1 and this complex fine-tunes the expression level of IL-20, it will be essential to assess the clinical meaning of the expression of FOXA1 in combination with the expression of Ell3 in ER(α) breast cancer patients.